Bolt Biotherapeutics (FRA:6LP0) 9-Day RSI: N/A (As of Jul. 05, 2026)


FRA:6LP0 Bolt Biotherapeutics Inc FRA:6LP0
55 GF Score
Price €5.18
GF Value €11.36
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-05), Bolt Biotherapeutics's 9-Day RSI is N/A.

The industry rank for Bolt Biotherapeutics's 9-Day RSI or its related term are showing as below:

FRA:6LP0's 9-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 53.73
* Ranked among companies with meaningful 9-Day RSI only.

Bolt Biotherapeutics  (FRA:6LP0) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Bolt Biotherapeutics 9-Day RSI Related Terms


FRA:6LP0 vs AIM, ERNA, RVPH: 9-Day RSI Comparison

For the Biotechnology subindustry, Bolt Biotherapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's 9-Day RSI falls into.


FRA:6LP0
55GF Score
Bolt Biotherapeutics Inc FRA:6LP0
9-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bolt Biotherapeutics  (FRA:6LP0) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of €5.18 is trading 54.4% below its estimated GF Value™ of €11.36.

Key valuation signals for FRA:6LP0:

  • 9-Day RSI: N/A
  • GF Value™: €11.36 vs. price of €5.18 (54.4% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bolt Biotherapeutics Business Description

Other Exchanges BOLT:USA
Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score

Get the complete analysis for FRA:6LP0

9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.18
Price
€11.36
GF Value